Otsuka expects to shell out $120M to settle Avanir's Nuedexta marketing probe
Avanir is nearing a deal with the U.S. Justice Department to settle allegations that it mismarketed Nuedexta, its drug for uncontrollable crying and laughing in neurological patients. And its parent company Otsuka thinks wrapping it up will cost $120 million.